Beyond Air, Inc.
Close on Oct 19, 2026
- Market cap
- $1.54M
- P/E (TTM)
- –
- Dividend yield
- –
About Beyond Air
Surgical & Medical Instruments & Apparatus, SIC 3841
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on developing and commercializing therapies utilizing nitric oxide (NO). The company's primary commercial offering is the LungFit PH system, an approved device designed to deliver therapeutic nitric oxide. In addition to commercializing this system, the organization explores novel therapeutic applications of nitric oxide through specialized subsidiaries, such as Beyond Cancer Ltd. and NeuroNos Ltd., which develop targeted product candidates categorized under pharmaceutical drug development.
The company's principal executive offices and headquarters are located in Garden City, New York. Beyond Air conducts operations across various international jurisdictions and clinical trial sites, maintaining affiliated corporate entities, subsidiaries, and activities tied to the United States, Australia, Bermuda, Ireland, and Cyprus. Its business relies on collaborations, third-party suppliers, manufacturing facilities, and clinical trial partners to support the production, regulatory review, and commercialization of its systems and developmental pipeline.
Summary of the business section of Beyond Air's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Beyond Air, Inc.
- Headquarters
- Garden City, NY
- Address
- 900 Stewart Avenue, Suite 301 11530
- Phone
- (516) 665-8200
- Employees
- 54, Mar 31, 2026
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- March 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- XAIR
- Exchange
- Nasdaq
- IPO date
- Jun 12, 2018
- Shares outstanding
- 1M, Aug 12, 2026
- Public float
- $15.50M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Aug 13, 2026; 1-for-20 reverse, Jul 13, 2026; 1-for-20 reverse, Aug 12, 2025; 1-for-20 reverse, Jul 14, 2025
- SEC CIK
- 1641631
- CUSIP
- 08862L301
- ISIN
- US08862L3015
- LEI
- 549300GFTTTXX5728360
- EIN
- 47-3812456
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Scott Goodman | Chief Executive Officer, Director | 34,822 |
| Steven A. Lisi | CEO and Chairman of the Board, Director | 3,327,411 |
| Daniel J. Moorhead | Chief Financial Officer | 4,340 |
| Michael A. Gaul | Chief Operating Officer | 94,150 |
| Douglas Quinton Larson | Chief Financial Officer | 27,548 |
| Yoori Lee | Director | 12,654 |
| Robert Carey | Director | 5,553,490 |
| Erick Lucera | Director | 43,608 |
| William P. Forbes | Director | 14,855 |
| Ron Bentsur | Director | 144,736 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Steve Lisi has served as our PEO since July 1, 2017. | $816.14K | -$792.21K | $435.07K | $4 | – |
| FY2024 Steve Lisi has served as our PEO since July 1, 2017. | $1.73M | -$4.13M | $875.50K | $26 | – |
| FY2023 Steve Lisi has served as our PEO since July 1, 2017. | $6.88M | $6.77M | $2.17M | $101 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of March 31, 2026, we had 54 employees globally, all of whom were full-time employees.”
Corporate history
Events identified from SEC filings